Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 2, 2004, Pages 226-229

  Li, Shi Yong ^a   Yu, Bo ^a   An, Ping ^a   Wei, Jia Chen ^a   Zuo, Fu Yi ^a   Cai, Hui Yun ^a  

^a Beijing Military Region General Hospital   (China)

Author keywords

Colorectal tumor; FasL; Gene; Gene expression; Tumor metastasis

Indexed keywords

CARBOPLATIN; COMPLEMENTARY DNA; FAS LIGAND; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RESISTANCE; CELL SURVIVAL; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NITROBLUE TETRAZOLIUM TEST; RECTUM CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; FAS LIGAND PROTEIN; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TRANSFECTION;

EID: 2442637754     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Shirari K, Tsuji N. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997;94:6420-6425.
2. Suda T, Takahashi T, Golstein P. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
3. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997;18:240-244.
4. O Connell J, O. Sullivan GC, Collins JK. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-1082.
5. Chappell DB, Zaks TZ, Rosenberg SA. Human melanoma cells do not express Fas (Apo-I/CD95) ligand. Cancer Res 1999;59:59-62.
6. Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH. Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999;154:693-703.
7. Li SY, Yu B, An P. The killing effect of double suicide gene on colorectal cancer cells mediated by adenovirus. J Surg Chin 2001;39:577-579.
8. Ochiumi T, Tanaka S, Oka S, Hiyama T, Ito M, Kitadai Y, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 2004;24:539-547.
9. Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 2004;90:712-719.
10. Tuncbilek N, Karakas HM, Altaner S. Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 2004; 1:120-123.
11. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279-287.
12. Cao ZX, Chen XP, Wu ZD. Changes of immune function in patients with liver cirrhosis after splenectomy combined with resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003;2:562-565.
13. Fang CH, Zhang W, Zhu XY, Gong JQ, Zhang GQ. The expression of c-kit and proliferating cell nuclear antigen in oval cells of rats with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003;2:537-544.
14. Chen J, Wang L, Li K, Lu YY. Cloning and expression of the gene of augmenter of liver regeneration of yeast cells. Hepatobiliary Pancreat Dis Int 2002;1:87-91.
15. Jia CK, Wang Y, Zheng SS, Zhang AB. Allolymphocyte apoptosis induced by solubale liver specific antigen. Hepatobiliary Pancreat Dis Int 2003;2:184-190.
16. Shen BY, Li HW, Regimbeau JM, Beighiti J. Recurrence after resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002;1:401-405.
17. Wu GS, Wang JH, Liu ZR, Zou SQ. Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2002;1:429-433.
18. Glover C, Douse P, Kane P. Accuracy of investigations for asymptomatic colorectal liver metastases. Dis Colon Rectum 2002;45:476-484.
19. Song E, Chen J, Ouyang N. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001;85:1047-1054.
20. Cai SR, He YL, Huang MJ, Peng JS, Wang JP, Zhan WH. The effect of FasL gene transfer to islet cells on pancreatic islet allografts. Hepatobiliary Pancreat Dis Int 2003;2:308-312.
21. Rajashekhar G, Loganath A, Roy AC, Mongelli JM. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines. Gynecol Oncol 2003;91:101-111.
22. Ungefroren H, Voss M, Henne-Bruns D, Kremer B, Kalthoff H. CD95 resistance and Fas ligand synthesis as mechanism of defense by immunocompetent cells in pancreatic tumors. Langenbecks Arch Chir Suppl Kongressbd 1998;115:63-67.
23. Chen YL, Chen SH, Wang JY, Yang BC. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 2003;171:1183-1191.
24. Houston A, Waldron-Lynch F, Bennett MW. Fas Ligand mediates immune privilege and not neutrophil recruitment in colon cancer in vivo. Gastroenterology 2000;118:A443
25. Reina JJ, Aparicio J, Salvador J, Pica JM, Rueda A, Lorenzo A, et al. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2003;52:339-345.
26. Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 2003;23: 1773-1777.
27. Pentheroudakis G, White J, Davis J, Brown I, Vasey P. Concurrent ovarian-type primary peritoneal adenocarcinoma and peritoneal choriocarcinoma. A case report and review of the literature. Gynecol Oncol 2004;92:697-700.
28. Mackay HJ, O'Brien M, Hill S, Lees SM, Thatcher N, Smith IE, et al. A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer. Clin Oncol 2003;15:181-185.
29. Oliver L, Cordel S, Barbieux I. Resistance to apoptosis is increased during metastatic dissemination of colon cancer. Clin Exp Metastasis 2002;19:175-180.